← Back to Clinical Trials
Recruiting NCT04354064

NCT04354064 Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04354064
Status Recruiting
Phase
Sponsor Washington University School of Medicine
Condition Healthy Volunteer
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2019-05-29
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2019-05-29 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.

Eligibility Criteria

Inclusion Criteria: * Eligible healthy donors will be at least 18 years of age. Exclusion Criteria: * Healthy donors younger than 18 years of age

Contact & Investigator

Central Contact

Melissa Reimers, M.D.

✉ cbumb@wustl.edu

📞 314-362-7249

Principal Investigator

Melissa Reimers, M.D.

PRINCIPAL INVESTIGATOR

Washington University School of Medicine

Frequently Asked Questions

Who can join the NCT04354064 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Volunteer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04354064 currently recruiting?

Yes, NCT04354064 is actively recruiting participants. Contact the research team at cbumb@wustl.edu for enrollment information.

Where is the NCT04354064 trial being conducted?

This trial is being conducted at St Louis, United States.

Who is sponsoring the NCT04354064 clinical trial?

NCT04354064 is sponsored by Washington University School of Medicine. The principal investigator is Melissa Reimers, M.D. at Washington University School of Medicine. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology